GALT Insider Trading (Galectin Therapeutics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 40.70%

Insider Buying (Last 12 Months): $23,050.00

Insider Selling (Last 12 Months): $201,900.00

Galectin Therapeutics Insider Trading History Chart

Galectin Therapeutics Share Price & Price History

^$2.62

▲ +0.11 (4.38%)

As of 04/9/2021 01:00 AM ET

Days: 30 | 90 | 365

100X Gains On Tap as Under-the-Radar Green-Tech Stock Soars

From Resource Stock Digest | Ad

Searching for the next 1,000% stock winner? Look no further than key Green-Techs that are driving the EV, Solar & 5G booms. Silver is the #1 element in the Green Energy Revolution & we’ve found the top silver gem – undiscovered at 10-cents per share – that’s fueling the path to a carbon-free world.

Get the details here...

Galectin Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/5/2021	Kevin D Freeman	Director	Buy	5,000	$2.04	$10,200.00	23,469
4/1/2021	Fund L.P. 10X	Major Shareholder	Sell	10,000	$2.16	$21,600.00
2/2/2021	Fund L.P. 10X	Major Shareholder	Sell	10,000	$2.04	$20,400.00
1/11/2021	Gilbert F Amelio	Director	Sell	60,000	$2.17	$130,200.00	60,614
10/13/2020	Fund L.P. 10X	Major Shareholder	Sell	10,000	$2.97	$29,700.00
9/4/2020	Kevin D Freeman	Director	Buy	5,000	$2.57	$12,850.00	23,469
3/19/2020	Kevin D Freeman	Director	Buy	6,000	$1.69	$10,140.00
1/17/2020	Fund L.P. 10X	Major Shareholder	Sell	10,000	$2.97	$29,700.00
11/15/2019	Kevin D Freeman	Director	Buy	3,000	$3.36	$10,080.00	23,469
10/10/2019	Fund L.P. 10X	Major Shareholder	Sell	17,000	$3.73	$63,410.00
9/6/2019	Kevin D Freeman	Director	Buy	1,290	$3.71	$4,785.90	23,469
5/31/2019	Jack W Callicutt	CFO	Buy	2,354	$4.28	$10,075.12	3,614
5/31/2019	Richard E Uihlein	Director	Buy	4,680,606	$4.28	$20,032,993.68	3,128,489
4/9/2019	Richard E Uihlein	Director	Buy	20,700	$4.82	$99,774.00	2,628,489
4/5/2019	Kevin D Freeman	Director	Buy	500	$4.73	$2,365.00	22,043
2/22/2019	Marc Rubin	Director	Sell	51,185	$6.02	$308,133.70	13,581
2/8/2019	Kevin D Freeman	Director	Buy	1,500	$4.29	$6,435.00	22,043
1/31/2019	Gilbert F Amelio	Director	Sell	30,000	$5.00	$150,000.00
1/29/2019	Richard E Uihlein	Director	Buy	51,500	$4.87	$250,805.00	2,538,289
9/25/2018	Kary Eldred	Director	Buy	2,000	$6.10	$12,200.00	41,382
9/10/2018	Gilbert S Omenn	Director	Sell	19,370	$6.02	$116,607.40	56,561
9/7/2018	Gilbert S Omenn	Director	Sell	11,000	$6.03	$66,330.00	56,561
9/4/2018	Marc Rubin	Director	Sell	11,900	$6.58	$78,302.00
8/30/2018	Marc Rubin	Director	Sell	58,100	$6.08	$353,248.00	84,581
6/25/2018	Joel Lewis	Director	Buy	1,000	$7.06	$7,060.00	51,480
6/20/2018	Jack W Callicutt	CFO	Sell	226,000	$8.61	$1,945,860.00	103,993
6/18/2018	Fund L.P. 10X	Major Shareholder	Sell	151,860	$8.61	$1,307,514.60
6/18/2018	James C Czirr	Director	Sell	60,000	$9.06	$543,600.00
6/15/2018	James C Czirr	Director	Sell	15,475	$8.47	$131,073.25
6/14/2018	Fund L.P. 10X	Major Shareholder	Sell	76,385	$8.28	$632,467.80
6/13/2018	Harold H Shlevin	COO	Sell	43,698	$7.41	$323,802.18
6/13/2018	James C Czirr	Director	Sell	208,140	$7.17	$1,492,363.80
6/13/2018	Peter G Traber	CEO	Sell	100,000	$7.51	$751,000.00	207,333
6/11/2018	Harold H Shlevin	COO	Sell	115,054	$5.84	$671,915.36	103,914
6/11/2018	Jack W Callicutt	CFO	Sell	120,000	$5.85	$702,000.00	101,260
6/8/2018	Jack W Callicutt	CFO	Sell	100,000	$5.75	$575,000.00	101,260
6/8/2018	James C Czirr	Director	Sell	110,000	$5.88	$646,800.00
6/8/2018	Peter G Traber	CEO	Sell	70,000	$5.86	$410,200.00	177,333
6/7/2018	Harold H Shlevin	COO	Sell	109,969	$5.20	$571,838.80	58,094
6/5/2018	Harold H Shlevin	COO	Sell	20,831	$5.15	$107,279.65	59,414
6/4/2018	Fund L.P. 10X	Major Shareholder	Sell	50,000	$5.12	$256,000.00
6/1/2018	Harold H Shlevin	COO	Sell	119,200	$5.06	$603,152.00	103,914
5/31/2018	Jack W Callicutt	CFO	Sell	46,651	$5.00	$233,255.00	47,911
4/16/2018	Theodore Daniel Zucconi	Director	Sell	4,000	$3.58	$14,320.00	5,083

SEC Filings (Institutional Ownership Changes) for Galectin Therapeutics (NASDAQ:GALT)

17.58% of Galectin Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Galectin Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/2/2021	FormulaFolio Investments LLC	12,710	$28K	0.0%	N/A	0.022%
2/19/2021	JPMorgan Chase & Co.	103,713	$0.23M	0.0%	+378.5%	0.182%
2/12/2021	Raymond James Financial Services Advisors Inc.	18,229	$41K	0.0%	N/A	0.032%
2/11/2021	Northern Trust Corp	452,957	$1.01M	0.0%	-2.8%	0.794%
2/11/2021	Barclays PLC	12,006	$27K	0.0%	-30.5%	0.021%
2/10/2021	Renaissance Technologies LLC	15,627	$35K	0.0%	N/A	0.027%
2/10/2021	D.A. Davidson & CO.	767,321	$1.72M	0.0%	-10.1%	1.344%
2/9/2021	Wells Fargo & Company MN	96,815	$0.22M	0.0%	+69.1%	0.170%
2/5/2021	BlackRock Inc.	2,598,089	$5.82M	0.0%	+3.8%	4.552%
2/4/2021	Cambridge Investment Research Advisors Inc.	179,556	$0.40M	0.0%	-6.1%	0.315%
11/13/2020	Morgan Stanley	31,579	$85K	0.0%	-51.6%	0.055%
11/12/2020	JPMorgan Chase & Co.	21,674	$72K	0.0%	-22.6%	0.038%
11/10/2020	State Street Corp	698,113	$1.86M	0.0%	+1.5%	1.223%
11/9/2020	The Manufacturers Life Insurance Company	26,819	$72K	0.0%	+23.4%	0.047%
11/9/2020	LPL Financial LLC	18,584	$50K	0.0%	-34.2%	0.033%
11/6/2020	BlackRock Inc.	2,503,111	$6.68M	0.0%	-0.4%	4.385%
10/29/2020	Cambridge Investment Research Advisors Inc.	191,195	$0.51M	0.0%	-5.8%	0.335%
10/13/2020	Brookstone Capital Management	12,710	$34K	0.0%	N/A	0.022%
9/15/2020	Two Sigma Advisers LP	11,800	$36K	0.0%	N/A	0.021%
8/25/2020	Nuveen Asset Management LLC	181,943	$0.56M	0.0%	+39.9%	0.319%
8/14/2020	Bank of America Corp DE	10,895	$33K	0.0%	+145.8%	0.019%
8/14/2020	Advisor Group Holdings Inc.	1,012,430	$3.10M	0.0%	+17.1%	1.775%
8/13/2020	Vivaldi Capital Management LLC	15,439	$40K	0.0%	+44.7%	0.027%
8/12/2020	Goldman Sachs Group Inc.	20,794	$64K	0.0%	+24.7%	0.036%
7/31/2020	UBS Group AG	12,401	$38K	0.0%	-50.4%	0.022%
6/19/2020	State Street Corp	663,783	$1.30M	0.0%	-1.1%	1.164%
5/18/2020	Advisor Group Holdings Inc.	864,275	$1.69M	0.0%	N/A	1.515%
5/15/2020	Morgan Stanley	55,511	$0.11M	0.0%	-66.1%	0.097%
5/15/2020	Two Sigma Investments LP	16,932	$33K	0.0%	N/A	0.030%
5/14/2020	Wells Fargo & Company MN	45,658	$89K	0.0%	+45.1%	0.080%
5/14/2020	Geode Capital Management LLC	561,368	$1.10M	0.0%	+3.1%	0.984%
5/14/2020	Deutsche Bank AG	13,826	$28K	0.0%	-35.1%	0.024%
5/14/2020	MML Investors Services LLC	28,541	$56K	0.0%	+28.9%	0.050%
5/14/2020	Nuveen Asset Management LLC	130,022	$0.26M	0.0%	+21.2%	0.228%
5/12/2020	JPMorgan Chase & Co.	40,599	$79K	0.0%	+209.2%	0.071%
5/11/2020	State Street Corp	663,783	$1.30M	0.0%	-1.1%	1.164%
5/8/2020	Cambridge Investment Research Advisors Inc.	204,824	$0.40M	0.0%	+7.4%	0.359%
5/2/2020	SG Americas Securities LLC	12,876	$25K	0.0%	N/A	0.023%
5/1/2020	BlackRock Inc.	2,553,541	$5.01M	0.0%	-1.1%	4.477%
5/1/2020	UBS Group AG	25,009	$49K	0.0%	-51.3%	0.044%
3/5/2020	Nuveen Asset Management LLC	107,272	$0.31M	0.0%	-12.2%	0.189%
2/20/2020	Geode Capital Management LLC	544,573	$1.56M	0.0%	+15.7%	0.957%
2/18/2020	Ameritas Investment Company LLC	10,782	$31K	0.0%	N/A	0.019%
2/14/2020	Goldman Sachs Group Inc.	32,076	$92K	0.0%	-22.9%	0.056%
2/14/2020	UBS Group AG	51,319	$0.15M	0.0%	+53.5%	0.090%
2/13/2020	Oxford Asset Management LLP	27,906	$80K	0.0%	N/A	0.049%
2/13/2020	Renaissance Technologies LLC	39,100	$0.11M	0.0%	N/A	0.069%
2/12/2020	Advisor Group Inc.	799,846	$2.29M	0.0%	+3.0%	1.406%
2/10/2020	Barclays PLC	40,060	$0.12M	0.0%	+101.6%	0.070%
2/6/2020	State Street Corp	671,117	$1.92M	0.0%	+20.7%	1.180%
2/4/2020	Virtu Financial LLC	54,738	$0.16M	0.0%	N/A	0.096%
2/4/2020	Cambridge Investment Research Advisors Inc.	190,680	$0.55M	0.0%	-18.4%	0.335%
11/27/2019	Millennium Management LLC	10,161	$37K	0.0%	-91.5%	0.018%
11/27/2019	Squarepoint Ops LLC	13,901	$51K	0.0%	+37.5%	0.024%
11/27/2019	California State Teachers Retirement System	62,417	$0.23M	0.0%	+25.7%	0.110%
11/27/2019	State Street Corp	556,124	$2.04M	0.0%	+7.9%	0.978%
11/5/2019	D.A. Davidson & CO.	820,158	$3.01M	0.1%	+3.7%	1.444%
10/17/2019	Wedbush Securities Inc.	21,498	$79K	0.0%	-12.2%	0.038%
8/20/2019	Amussen Hunsaker Associates LLC	17,090	$71K	0.0%	N/A	0.030%
8/15/2019	Cambridge Investment Research Advisors Inc.	232,554	$0.97M	0.0%	+32.0%	0.411%
8/15/2019	Centaurus Financial Inc.	16,563	$69K	0.0%	+20,098.8%	0.029%
8/14/2019	D. E. Shaw & Co. Inc.	19,498	$81K	0.0%	+19.3%	0.034%
8/14/2019	Vivaldi Capital Management LLC	10,668	$44K	0.0%	N/A	0.019%
8/14/2019	Morgan Stanley	53,645	$0.22M	0.0%	-9.0%	0.095%
8/14/2019	Vanguard Group Inc.	1,734,324	$7.20M	0.0%	+7.8%	3.804%
8/13/2019	BlackRock Inc.	2,045,111	$8.49M	0.0%	+243.4%	4.485%
8/13/2019	MML Investors Services LLC	28,793	$0.12M	0.0%	+38.5%	0.063%
8/13/2019	D.A. Davidson & CO.	790,874	$3.28M	0.1%	+4.8%	1.735%
8/13/2019	Northern Trust Corp	134,116	$0.56M	0.0%	+49.4%	0.294%
8/12/2019	Bank of New York Mellon Corp	95,315	$0.40M	0.0%	+392.5%	0.209%
8/12/2019	BT Wealth Management LLC	57,009	$0.19M	0.1%	+14.0%	0.125%
8/10/2019	Charles Schwab Investment Management Inc.	75,092	$0.31M	0.0%	N/A	0.165%
8/1/2019	Wedbush Securities Inc.	24,498	$0.10M	0.0%	+36.1%	0.054%
7/31/2019	Cutter & CO Brokerage Inc.	89,240	$0.37M	0.1%	N/A	0.196%
7/31/2019	Advisor Group Inc.	807,175	$3.35M	0.0%	+16.5%	1.771%
6/30/2019	Commonwealth Equity Services LLC	15,247	$63K	0.0%	+25.1%	0.033%
6/30/2019	WINTON GROUP Ltd	40,279	$0.17M	0.0%	+37.5%	0.088%
6/16/2019	Belpointe Asset Management LLC	26,998	$0.14M	0.0%	N/A	0.059%
5/10/2019	Alpine Global Management LLC	19,093	$98K	0.0%	-18.2%	0.042%
5/9/2019	Advisor Group Inc.	692,589	$3.54M	0.0%	+2.7%	1.521%
5/8/2019	Cambridge Investment Research Advisors Inc.	176,222	$0.90M	0.0%	N/A	0.387%
5/8/2019	Laurion Capital Management LP	171,543	$0.88M	0.0%	+81.7%	0.377%
4/4/2019	Tibra Equities Europe Ltd	72,685	$0.37M	0.0%	N/A	0.160%
2/15/2019	BT Wealth Management LLC	50,000	$0.25M	0.1%	N/A	0.122%
2/15/2019	Cetera Advisor Networks LLC	19,021	$66K	0.0%	-43.6%	0.046%
2/14/2019	MML Investors Services LLC	26,926	$92K	0.0%	+55.8%	0.065%
2/14/2019	First Foundation Advisors	18,240	$63K	0.0%	-92.6%	0.044%
2/14/2019	Barclays PLC	174,603	$0.60M	0.0%	+2,711.6%	0.424%
2/13/2019	Geode Capital Management LLC	227,175	$0.78M	0.0%	+7.3%	0.552%
2/11/2019	Advisor Group Inc.	674,291	$2.31M	0.0%	+12.8%	1.639%
2/8/2019	BlackRock Inc.	604,268	$2.07M	0.0%	+0.4%	1.469%
2/8/2019	Stratos Wealth Partners LTD.	40,950	$0.14M	0.0%	+45.5%	0.100%
1/29/2019	D.A. Davidson & CO.	718,923	$2.47M	0.0%	+4.3%	1.748%
12/13/2018	Vanguard Group Inc	1,432,576	$8.61M	0.0%	+18.7%	3.482%
11/23/2018	Belpointe Asset Management LLC	31,129	$0.19M	0.0%	-28.5%	0.076%
11/23/2018	Vanguard Group Inc.	1,432,576	$8.61M	0.0%	+18.7%	3.482%
11/13/2018	First Foundation Advisors	245,740	$1.48M	0.1%	N/A	0.601%
11/13/2018	Monashee Investment Management LLC	65,056	$0.39M	0.1%	N/A	0.159%
11/13/2018	Virtu Financial LLC	17,752	$0.11M	0.0%	N/A	0.043%
11/13/2018	D.A. Davidson & CO.	689,278	$4.14M	0.1%	+5.0%	1.685%

Data available starting January 2016

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Today's Range

Now: $2.62

$2.46

$2.75

50 Day Range

MA: $2.26

$2.03

$2.80

52 Week Range

Now: $2.62

$1.65

$3.85

Volume

598,105 shs

Average Volume

602,928 shs

Market Capitalization

$149.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.04

Who are the company insiders with the largest holdings of Galectin Therapeutics?

Galectin Therapeutics' top insider investors include:

Richard E Uihlein (Director)
Gilbert F Amelio (Director)
Kevin D Freeman (Director)
Jack W Callicutt (CFO)
Fund LP 10X (Major Shareholder)